ClinicalTrials.gg
RecruitingNCT05543200Updated Aug 13, 2026

BPH Global Registry

An observational study in Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Société Internationale d'Urologie. Recruiting at 30 sites in 21 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Société Internationale d'Urologie · Observational

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,500
Ages
18 Years and older
Sex
Male
01

Study summary

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.

Read the detailed description

Due to a growing and aging population, cases of benign prostatic hyperplasia (BPH) have been on a steady rise. Studies show that by age 80, 90% of men experience BPH. (Garraway, Lee, Collins, 1991) Thus, treatment of BPH is one of the most performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been somewhat standardized. The purpose of this study is to create an ongoing prospective registry to record demographic data and clinical outcomes after medical therapy or different surgical interventions for BPH. The specific aims of the registry are to analyze demographic patterns and baseline characteristics of men undergoing surgical and medical treatments for BPH, to assess global practice patterns for various surgical and medical treatments of BPH, and to assess key outcomes for uni- and multi-modal treatments of BPH.

The ongoing global registry will provide important baseline data, functional outcomes, and complications following medical and/or surgical intervention for men with symptomatic BPH. The intention of the registry is to provide real world usage data that may be used for future investigations. It will allow providers to identify areas of interest, areas of unusually low usage or areas of unusual preference on a global scale. It will also shed light on global preferences for unimodal or multimodal approaches to treatments.

The registry has been developed using novel database technology, providing an easy-to-use user interface, which enables future creation of patient portals and Electronic Medical Record (EMR) integration.

As this is not an experimental setting, there will be no interventions made on behalf of the registry.

This is a prospective longitudinal ongoing registry. The study will include medical records of all men ≥18 years old who have a primary diagnosis of BPH with Lower Urinary Tract Symptoms (LUTS) that are prescribed BPH medications, or a surgical intervention. Data extraction includes baseline data, peri-operative data, and follow-up data. Baseline data includes validated patient reported outcome tools, including International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EjD), as well as Quality of Life (QoL), maximum flow rate (Qmax), Post-void residual (PVR), Prostate Specific Antigen (PSA), and Testosterone. Complications such as Bleeding, Urinary Tract Infection (UTI), Incontinence, Stricture, Retrograde ejaculation, and Erectile Dysfunction (ED) are also tracked from Baseline through Follow-up.

The registry will run for 3 years with no end point for follow-up. For three years, various research studies will be formulated, and the results will be published. The possibility of extending the study for continued follow-up will be evaluated.

A built-in quality control using data validation during the input process decreases the chance that invalid data will be entered or that datapoints will be omitted. Periodic audits will be performed to verify accuracy of source data by our audit committee based on our audit committee guidelines.

Records and cases of all men with a primary diagnosis of BPH with LUTS that are prescribed BPH medications, or a surgical intervention will be identified and included in the registry. All data is hashed (i.e., protected from decryption) except for a medical record number (MRN), which will be used to add follow-up data to the patient's record. This number is encrypted and linked to the hashed and randomly generated institution code. For security purposes, biographical information is not saved on the registry.

The registry provides secure access to registered users using a web browser. Registrations are site-specific, which means that users can only access the data that is specific to their own site. The registry application and databases are hosted on secure, encrypted servers behind a firewall. They can only be accessed by registered users via a specific port.

02

Conditions studied

  • Benign Prostatic Hyperplasia
  • Lower Urinary Tract Symptoms

Keywords

  • BPH, Registry, LUTS
03

In context

Prostatic Hyperplasia

827 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

This study's planned enrollment of 7,500 is above the median of 250 across 177 observational studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Société Internationale d'Urologie is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients >18 years with symptomatic BPH with LUTS who are planned for medical or surgical intervention are eligible for this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention

Exclusion criteria

Exclusion Criteria:

  • Non-symptomatic BPH
  • No treatment prescribed for BPH
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • All Participants

    All men who have a primary diagnosis of BPH with LUTS that are prescribed BPH medications or a surgical intervention.

06

What researchers measure

Primary outcomes

  1. International Prostate Symptom Score (IPSS)

    Comparison of mean IPSS score change between baseline and at each follow-up during the course of the study. The scale goes from 0 (Mild) to 35 (Severe).

    Time frame: 36 months

  2. Quality of Life (QoL)

    Comparison of mean QoL score change between baseline and at each follow-up during the course of the study. The scale is a single question which ranges from 0 to 6, with higher numbers indicating a worse quality of life.

    Time frame: 36 months

  3. Post-Void Residual (PVR)

    Comparison of mean PVR change between baseline and at each follow-up during the course of the study.

    Time frame: 36 months

  4. Complications (including incontinence)

    Type and Clavien grade incidences across all surgical interventions.

    Time frame: 36 months

Secondary outcomes

  1. Prostate Volume (cc)

    Comparison of mean Prostate Volume change between baseline and at each follow-up during the course of the study.

    Time frame: 36 months

  2. Qmax

    Comparison of mean Qmax change between baseline and at each follow-up during the course of the study.

    Time frame: 36 months

  3. Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD)

    Comparison of mean MSHQ-EjD score change between baseline and at each follow-up during the course of the study. The scale ranges from 1 to 15 with a higher score indicating better sexual functioning.

    Time frame: 36 months

  4. Sexual Health Inventory for Men (SHIM)

    Comparison of mean SHIM score change between baseline and at each follow-up during the course of the study.

    Time frame: 36 months

07

Study locations

22 of 30 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05543200
Lead sponsor
Société Internationale d'Urologie
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Mar 13, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 13, 2026

Study contacts

Mihir Desai, MD
Contact
mihir.desai@med.usc.edu
+1 (323) 865 3700
Eduardo Gutierrez, PhD
Contact
eduardo.gutierrez@siu-urology.org
+1 514 875-5665 ext. 35
Mihir Desai, MD
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion